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SUMMARY 
Out of 692 patients registered in the lithium clinic, King George's Medical College, Lucknow, 
12? patients suffering from affective disorders, receiving lithium for at least 6 months continuously, hav-
ing had at least 5 serum lithium estimitioris done and having been evaluated at least once in 6 months 
while on follow-up, w:re analysed with a view to study the relapses. About one-third patients suffered 
no rctaps; while on lithium. The study revealed that longer the duration of lithium treatment lesser 
were the frequancy, number, intensity and duration of manic/depressive relapses. Majority of patients 
were maiatained on the lower side (0.5-0.8 mEq/L) of the usually recommended therapeutic range 
(0.6-1.2 mEq/L) for lithium prophylaxis. Commonly observed side effects include fine tremors, mus-
cular weakiess, polyuria, polydipsia and constipation. All the side effects were easily managed and 
none had a fatal sides-effect. A reappraisal in the light of existing literature of lithium prophylaxis 
on manic depressive psychosis is done. 
Ever since Cade (1949) observed 
the antimanic effect of lithium and 
Schou et al. (1954) conducted extensive 
clinical studies to elucidate its applica-
tion in the treatment of Affective Dis-
orders, reports continue to appear in 
the world literature which affirm the 
element's, unique position in the phar-
macotherapeutic armamentarium of psy-
chiatrists. 
Hartigan (1963) for the first time 
reported on the prophylactic effects of 
lithium on manic as well as depressive 
episodes. This property, of lithium was 
later on confirmed by studies comparing 
frequency and intensity of episodes of 
mania and depression before and after 
administration of lithium (Baaslrup etal., 
1970, Coppen et al., 1971; Hullin et al. 
1972; and Prien et al., 1973a) and 
also through controlled trials involving 
placebo and imipramine (Fieve et al., 
1968; Fieve and Mendelewicz, 1972; 
Prien et al., 1973b and Stallone et al., 
1973). As a result of the modifying 
influences introduced by the therapeutic 
activity of lithium it has now become 
essential to view the patient and his 
illness for a much longer period. 
However, in India, very few studies 
have highlighted the role of lithium as 
an antimanic-depressive drug (Prakash 
and Sethi, 1978; Venkoba Rao and 
Hariharsubramamam, 1978; Narayanan 
et al., 1979; Tandon etal., 1981 and 
Venkoba Rao et al., 1982). The most 
obvious reason for such scanty informa-
tion is the existence of very few lithium 
clinics primarily because of inadequate 
facilities to monitor lithium therapy in 
a majority of centres across the country. 
The present communication is based on 
data collected at our clinic which has 
been in existence for more than 7 years. 
MATERIAL AND METHODS 
The Lithium Clinic was established 
in the Department of Psychiatry, King 
George's Medical College, Lucknow in 
1977. Since then the clinic has been 
1. Professor and Head 
2. Chief Resident 
3. Lecturer  t 
Department of Psychiatry, King George's Medical College, Lucknow. 378  B. B. SETHI el al. 
providing specialized services to the 
vast population of the state of Uttar 
Pradesh and surrounding regions of 
North India. The clinic functions on 
all weekdays and caters to the patients 
of our hospital, private clinics, and 
referrals from other psychiatric hospitals. 
Besides the present study, antipsychotic 
effects of lithium in schizophrenia, effect 
of lithium on memory and renal func-
tions, chronic myeloid leokemia during 
lithium therapy (cas: report) and mega-
loblastic anaemia secondary to lithium 
(case report) have also been studied 
in the clinic. Lithium and its role in 
controlling aggression b;ing studied 
presently. 
This present report is an open 
study without involving control or a 
comparison with other drugs or placebo. 
Each patient served as his own control 
and the comparison has been betweer. 
the pre and post lithium characteristics 
of recurrences. Other open and single 
blind studies have been reported (Schou, 
1959; Wharton and Fieve, 1966; Blin-
der, 1968: Vander Velde, 1970 and 
Venkoba Rao et al., 1982) and found 
to be quite valid on reappraisal following 
the controlled studies referred to earlier. 
Over a period of 7 years 692 
patients from our and other psychiatric 
hospitals and private clinics were regis-
tered in the lithium clinic and were 
available for evaluation on one or more 
occasions. Compichensive information 
however (especially follow-up evalua-
tions), was available for our hospital 
patients only, since patients from other 
sources were being followed up at their 
respective clinics/hospitals Althougr 
patients belonging to our hospital num-
bered 285, the present report refers to 
122 subjects since they fulfilled the 
minimum criteria of 1) receiving lithium 
for at least 6 months continuously 2) 
having had at least 5 serum lithium 
estimations done and 3) having been 
evaluated at least once in 6 months 
while on follow-up. 
Before a patient was started on li-
thium therapy, he'she was assessed for 
suitability; the process involving critical 
evaluation of clinical data including diag-
nosis (according to International Classi-
fication of Diseases-Ninth Revision, W. 
H. O., 1977) and biochemical measures 
including a complete haemogram and 
urinalysis, blood urea, blood sugar, 
serum creatinine, serum chloesteral, 
serum electrolytes (Na+,K
+), liver func-
tion tests, ECG and weight charting. 
Other specialized investigations were 
done as and when required. Ii patients 
taken up for litl ium therapy, lithium 
carbonate was administered 300-1650 
mg'day in two or three divided doses. 
After 48 to 72 hours of commencement 
of lithium blood samples were drawn 
twelve hours after the last oral dose of 
lithium. The serum lithium was esti-
mated by flame photometry, using Am-
disen's method (Amdisen, 1967). Two 
or three estimations were done at weekly 
intervals and the dose was adjusted 
according to the clinical condition and 
also to keep the serum levels within the 
therapeutic range. There after, for the 
first three months, the patients were 
reviewed once in 2-3 weeks and later at 
longer intervals. During each review 
serum lithium was estimated, besides 
recording clinical assessment, side-effects, 
weight charting and use of other conco-
mitant medication. Every patient was 
informed about possible side-effects and 
an instruction sheet for the same pro-
vided. The follow-up record was main-
tained on a lithogram. 
The criteria for relapses were the 
persistence of disturbed mood and bio-
logical symptoms like insomnia, anorexia 
and alteration of psychomotor activity 
for more than 72 hours (Venkoba Rao 
et al., 1982). LITHIUM IN AFFECTIVE DISORDERS  379 
OBSERVATIONS 
Characteristics of the Sample: 
TABLE I—Churacteiistics of the sample 
Sex  Male 
Female 
M. D. P. Unipolar-
mania (296.0 i 
N 
108 
14 
16 
% 
88.5 
11.5 
13.1 
Diagnosis 
M. D. P.-Unipolar- 18 14.8 
Depressed (296.1) 
M. D. P.-Bipolar- 56 45.9 
Mania (296.2) 
M. D. P.-3ipoUr- 32 26.2 
Depressed( 296.3) 
Duration 6 Moaths to 1 year 36 29.5 
oflithium 1 To 3 Years 52 42.6 
treatment 3 To 5 Years 22 18.0 
5 To 7 Years 12 9.9 
As shown in table-I the majority 
of patients were males (88.5%), having 
M. D. P. bipolar-mania as the most 
frequent diagnosis (45.9%) followed by 
M. D. P. bipolar-depressed (14.8%) 
and M. D. P. unipolar-mania (l
q.l%). 
The patients on lithium theraps' for 
1-3 years (42.6%) constituted the largest 
group followed by those on therapy from 
6 months to 1 year (29.5%), 3 to 5 years 
(18.0%) and 5-7 years (9.9%). 
Frequency of relapses: 
In regard to the frequency of manic 
depressive relapses in the different li-
thium intake groups, about one third 
of the sample (40 out of 122) had no 
relapse. Majority of the relapse.! pa-
tients had one or two manic and'or 
depressive relapses. The response was 
even better when categories of bipolar 
affective disorder and uiipolar mania 
only arc couriered (38 ovt of 104 had 
no relapse) indicating lithium to be 
less effective in the prophylaxis of uni-
polar depression (Table II). 
Relapses at follow-up: 
Table-Ill shows the number of 
patients relapsing at different years of 
follow-up in patients taking lithium for 
TABLE II—Frequency of relapses in lithium intake groups 
Poriod of lit'iium, intake  No. of patients Number of relapses 
Mania Depression 
12 3 4 12 3 4 
No relapses 
6_ Months to 1 year 
—Uaipolar 
—Bipolar 
1 To 3 years 
—Uaipolar 
—Bipolar 
3 To 5 years 
—-Unipolar 
—Bipolar 
5 To 7 years 
—Unipolar 
12 
24 
20 
32 
2 
20 
2 
16 
3 
10 
4 
2 
1 
2 
6 
4 
— 
— 
— 
4 
2 
— 
1 
— 
— 
1 
4 
13 
4 
5 
1 
2 
4 
3 
9 
1 
5 
— — 
— 1 
2 — 
6 — 
1 — 
1 1 
.2 
6 
6 
12 
8 
-Bipolar  12  2 2 11 3 2 1 — 380  B. B. SETHI el al. 
TABLE Wl^Relapses at Follow-up 
Period of lithium intake No. of 
patients 
No. of patients relapsing at year of follow-up 
Mania Depression 
1234567 1234567 
3 To 5 years 
—Unipolar 
—Bipolar 
5 To 7 years 
—unipolar 
—Bipolar 
2 
20 
— 
12 
11 7 3 1 — — 
2 4 — — — — — 
12 7 2 1 — — — 
642 1 — — — 6 2 —  — 1 1 
3-5 years and 5-7 years. While the 
number of bipolar patients having ma-
nic relapses during 1st year in the 3-5 
years lithium intake group were 11, 
they were decreased to 7,3 and 1 during 
2nd, 3rd and 4th year respectively and 
none in the 5th year. A similar pattern 
was seen in relation to depressive relapses 
in the same group and to manic relapses 
in the 5-7 yea.s lithium intake group. 
The number of patients having depres-
sive relapses during the 1st year in the 
later group were 6 and were decreased 
to 2 in the 2nd year, none during 3rd 
to 5th year ard only one patient had 
mild episodes of short duration during 
6th and 7th year. Thus, one is able to 
observe a reduction in the frequency of 
relapses as the duration of maintenance 
treatment with lithium increases and 
lithium to be equally effective in manic 
as well as depressive relapses in bipolar 
illness. 
Basic Data : 
Table IV and V reveal the basic 
data in regard to frequency of serum 
lithium estimations, mean serum lithium 
TABLE IV—Frequency of estimation and mean serum lithium levels 
Duration of lith- Frequency of serum No. of patients 
ium therapy lithium estimation 
Mean serum lithium 
levels (mEq/L) 
Range 
6 Months to 
1 Year 
1 To 3 
Years 
3 To 5 
Years 
5 To 7 
Years 
5—9 
10—14 
5—9 
10-14 
15—19 
20 & above 
5—9 
10—14 
15—19 
20 & above 
5—9 
10—14 
15—19 
20 & above 
26 
10 
26 
12 
8 
6 
6 
4 
6 
6 
— 
2 
* 
6 
0.61±0.23 
0.54-^0.22 
0.66-J-0.23 
0.65±0.19 
0.62±0.21 
0.72±0.24 
0.60^0.23 
0.59±0.15 
0.65^0.18 
0.56^0.31 
. . 
O.56±0.13 
0.71-^0.19 
0.76±0.21 
0.10—1.12 
0.06— .81 
0.13—1.36 
0.19—1.20 
0.30—1.25 
0.40—1.35 
0.12—1.20 
0.25—0.92 
0.22—1.06 
0.08—1.17 
0.38—0.78 
0.18—1.18 
0.10—1.25 T
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levels and relationship between the dose 
and serum levels in the four lithium in-
take groups. The frequency of serum 
lithium estimation was 5-14 times in 
6 months to 1 year group and 5-20 times 
and above in the other three groups. 
Majority of patients have mean serum 
lithium levels between 0.5 to 0.8 mEq/L 
and with the increase in the dosage of 
lithium these levels increased correspon-
dingly. 
Side effects 
Table VI shows the nature and fre-
quency of side-effects as seen in the 
TABLE VI— Side effects 
1. 
2. 
3. 
4. 
5. 
6. 
7. 
8. 
9. 
10. 
11. 
Side Effects 
Fiie tremors 
Muscular weakness 
Polydipsia 
Coistipition 
Polyurh, drowsiness, 
oedemi, anorexia 
Dryness of mouth 
Weight giin, bodyachi 
headache, distaste of 
mouth 
Diarrhoea 
N 
38 
32 
26 
24 
20 
12 
10 
8 
Nausea, dizziness, forget-
fulness, muscular cramps 
and f isciculations 6 
Vomitting 5 
Stomatitis, slurred spee-
ch, palpitation 4 
% 
(30.9) 
(26.1) 
(21.2) 
(19.6) 
(16.3) 
(9.8) 
(8.2) 
(6.5) 
(4.9) 
(4.1) 
(3.3) 
Each 
Each 
Each 
Each 
12. Blinking of eyes, Brea-
thlessness, heaviness of 
abdomen, blurring of 
vision, skin erruptions, 
facial grimacing 2 (1.6) Each 
13. Azzospermia, megalob-
lastic anaemia, chronic 
myeloid leukemia 1 (0-8) Each 
clinic sample. Fine tremors were most 
frequent (30.9%) followed by muscular 
weakness (26.1%), polydipsia (21.2%), 
constipation (19.6%), polyuria,, drowsi-
ness, oedema and anorexia (16.3% 
each). One patient each had azoos-
permia, megaloblastic anaemia and 
chronic myeloid leukemia. The side-
effects were easily managed and none 
had a fatal side-effect. 
DISCUSSION 
Our data offer strong support for 
the lithium proplylaxis in bipolar affec-
tive disorder. Out of 122 patients re-
ceiving lithium for a period between 6-
months to 7 years, 40 patients had no 
relapse. Eighty two patients experi-
enced recurrences while on continuous 
lithium treatment but they were marked 
by lessened frequency, number, intensity 
and duration. These relapses of mania 
or depression required lesser concomitant 
phenothiazines or antidepressants along 
witV lithium and only few of them re-
quired hospitalization or tre? tment with 
electroconvulsive therapy. Thus, there 
was a substantial reduction in cost in-
volved in the management of the patient. 
Such observations have been referred to 
by Fieve (1976) and Venkoba Rao et al. 
(1982). There have been numerous 
favourable reports on lithium prophylaxis 
ir. bipolar illness (Hartigan, 1963 ; 
Baastrup and Schou., 1967 ; Prien 
1979 and Narayanan et al., 1979) 
The placebo control studies have re-
vealed that about 30% of manic depre-
ssives on lithium experienced a relapse 
during a two-year followup period 
(Baastrup et al., 1970 ; Prien et al., 
1973 ; Stallone et al., 1973 ; Coppen 
et al., 1971). The relapse rate by con-
trast was 90% among those receiving 
placebo. 
The effectiveness of the prophylac-
tic effect in unipolar depressives has been LITHIUM IN AFFECTIVE DISORDERS  383 
advanced by Schou (1979) and Prien 
(1979) amongst others. Although in our 
series the number of unipolar depres-
sives was too small to help draw 
any firm conclusion, it was observed that 
as compared to bipolar illness or to uni-
polar mania, lithium was found to be 
less effective in the prophylaxis of uni-
polar depression. However, in the 
manic and depressive relapses of bipolar 
illness lithium was found to be equally 
effective. 
The retention of insight in a majority 
of patients enabled them to sense that the 
recurrence was around the corner and to 
report at the clinic earlier thereby fac-
ilitating early treatment and a quicker 
control of symptoms. In years to come 
there is a likelihood of change in the 
symptomatology of the manic depressive 
episodes when it is claimed that lithium 
specifically alters the core symptom viz. 
the i ffective and ideational features of 
the illness (Goodwin and Zis, 1979). 
One should therefore be prepared to 
recognize the truncated or metamorpha-
sed episodes of affective illness in patients 
already on lithium. This situation is 
analogous to the treated long term ill-
ness like tuberculosis (Venkoba Rao 
et al., 1982). 
The majority of our patients had 
mean serum lithium levels ranging from 
0.5 to 0.8 mEq/L thereby indicating 
that in our setting patients of affective 
disorder are well maintained at the 
lower side of the usually recommended 
maintainerce level i.e. 0.6—1.2 mEq/L. 
In all the four groups of lithium intake, 
a dose range of 300 mg. to 1500 mg was 
suffcient to bring about the desired cli-
nical response and an increase in the do-
sage of lithium is accompanied by a 
corresponding increase in the values of 
level which always remained within the 
recommended therapeutic range, though 
mostly on the lower side. Hullin (1979) 
suggested that the levels from 0.4 to 0.8 
mEq/L would suffice for prophylaxis, 
though recognizing the need for higher 
levels of 0.6—1.2 mEq/L for controlling 
acute manic episodes. 
The side-effects encountered during 
the course of lithium therapy in our clinic 
population were in one-third of the 
sample, a frequency which was lower than 
the reports of Hewick et al. (1977) 
who reported minor side-effects in over 
40% of patients stabilized on long-term 
lithium therapy and of Johnston et al. 
(1979) who observed side effects in about 
two-third of the patients. One of the 
reasons for this discrepancy may be due 
to the maintainence of our patients on 
the lower side of the therapeutic range 
the other reason can be due to cross cul-
tural variation. The frequency of fine 
tremors (30.97%), muscular weakness 
(26.1%), polydipsia (21.2%), constipa-
tion (19.6%) and polyuria (16.3%) as 
seen in our sample more or less corres-
pond to the reports in the literature. 
An attempt was made to correlate 
the side-effects with serum lithium levels 
and it was observed that below 0.3 
mEq/L diarrhoea was the most promi-
nantside effect which decreased on increa-
sing the dose of lithium carbonate. Bone 
et al. (1980) reported the most frequent 
cause of drop-out had been severe dia-
rrhoea on very low dosage. Above the 
serum level of 1.0 mEq/L along with 
usual side effects we observed muscular 
cramps, fasciculadons, slurred speech, 
blinking of eyes, facial grimacing and 
forgetfulness which were not noticed on 
lower levels. All the side effects were 
easily managed and no fatal side effect 
occurred in our sample although mega-
loblastic anaemia aid chronic myeloid 
leukemia were detected in one patient 
each. 
CONCLUSION 
Experiences with lithium at this 
centre provided further proof of its 384  B. B. SETHI it ol. 
therapeutic and prophylactic efficacy 
in bipolar and unipolar patients, though 
more in bipolars. The longer the dura-
tion of treatment leaser were the fre-
quency, number, intensity and duration 
of manic depressive relapse. Majority 
of patients were maintained on the 
lower side (0.5—0.8 rnEq/L) of the 
usually recommended therapeutic range 
(0.6—'1.2 mEq/L) for lithium prophy-
laxis. Commonly observed side effects 
include fiae tremors, muscular weakness, 
polyuria, polydipsia and constipation. 
All the side-effects were easily managed 
and none hud a fatal side-effect though 
megaloblastic anaemia, chronic myeloid 
leukemia and azoospermia were obser-
ved in one patient each. 
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